Cancer medicines

Trastuzumab deruxtecan

Trastuzumab deruxtecan

An antibody-drug conjugate delivering cytotoxic treatment through HER2 targeting.

Sources checked · Introductory guide

On this page

How it works

An ADC linking a HER2 antibody to a topoisomerase I inhibitor. Distinguish it from trastuzumab alone.[3]

Where it is used

Used in selected breast, gastric, lung and other cancers according to HER2 expression or mutation and prior treatment. Eligibility differs by setting.[1]

Key safety points

Interstitial lung disease or pneumonitis can be severe. Report new cough, breathlessness or fever immediately; confirm blood-count and heart monitoring.[2]

Questions for your care team

  • How do my HER2 results and prior treatment establish eligibility, and whom do I contact for lung symptoms?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. NCI · Fam-Trastuzumab Deruxtecan-nxki (opens in a new tab)
  2. MedlinePlus · Fam-Trastuzumab Deruxtecan-nxki (opens in a new tab)
  3. NCI Drug Dictionary · Fam-Trastuzumab Deruxtecan-nxki (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

Trastuzumab deruxtecan | Cancer Encyclopedia | My Chemo Diary